Parallel Advisors, LLC Ionis Pharmaceuticals Inc Transaction History

Parallel Advisors, LLC

$4.31 Billion
Q1 2025

A detailed history of Parallel Advisors, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 745 shares of IONS stock, worth $26,253. This represents 0.0% of its overall portfolio holdings.

Number of Shares

745

Previous 959 22.31%

Holding current value

$26,253

Previous $33,000 33.33%

% of portfolio

0.0%

Previous 0.0%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 07, 2025	SELL	$30.17 - $34.97 $6,456 - $7,483	-214 Reduced 22.31%	745 $22,000
Q4 2024 Feb 10, 2025	SELL	$33.73 - $40.36 $2,327 - $2,784	-69 Reduced 6.71%	959 $33,000
Q3 2024 Nov 13, 2024	BUY	$40.06 - $51.86 $15,863 - $20,536	396 Added 62.66%	1,028 $41,000
Q2 2024 Aug 08, 2024	BUY	$36.45 - $47.7 $2,187 - $2,862	60 Added 10.49%	632 $30,000
Q1 2024 May 06, 2024	BUY	$42.03 - $53.55 $294 - $374	7 Added 1.24%	572 $24,000
Q4 2023 Feb 09, 2024	SELL	$43.39 - $51.63 $4,599 - $5,472	-106 Reduced 15.8%	565 $28,000
Q3 2023 May 20, 2024	SELL	$38.5 - $47.13 $1,540 - $1,885	-40 Reduced 5.63%	671 $30,000
Q3 2023 Nov 13, 2023	SELL	$38.5 - $47.13 $1,540 - $1,885	-40 Reduced 5.63%	671 $30,000
Q2 2023 May 20, 2024	BUY	$34.73 - $43.33 $1,389 - $1,733	40 Added 5.96%	711 $29,000
Q2 2023 Aug 04, 2023	BUY	$34.73 - $43.33 $1,389 - $1,733	40 Added 5.96%	711 $29,000
Q1 2023 May 20, 2024	BUY	$33.58 - $41.2 $3,324 - $4,078	99 Added 17.31%	671 $23,000
Q4 2022 Feb 03, 2023	SELL	$37.12 - $46.52 $1,893 - $2,372	-51 Reduced 7.06%	671 $25,000
Q3 2022 Nov 10, 2022	SELL	$36.54 - $48.66 $73 - $97	-2 Reduced 0.28%	722 $32,000
Q2 2022 Aug 01, 2022	BUY	$31.71 - $43.0 $253 - $344	8 Added 1.12%	724 $27,000
Q1 2022 Apr 28, 2022	BUY	$29.88 - $37.04 $2,838 - $3,518	95 Added 15.3%	716 $26,000
Q4 2021 Jan 20, 2022	SELL	$25.61 - $35.1 $2,612 - $3,580	-102 Reduced 14.11%	621 $19,000
Q3 2021 Nov 02, 2021	BUY	$33.54 - $40.55 $9,894 - $11,962	295 Added 68.93%	723 $24,000
Q2 2021 Aug 06, 2021	SELL	$34.54 - $47.25 $87,524 - $119,731	-2,534 Reduced 85.55%	428 $17,000
Q1 2021 Apr 23, 2021	BUY	$42.51 - $63.78 $20,617 - $30,933	485 Added 19.58%	2,962 $133,000
Q4 2020 Feb 02, 2021	BUY	$45.3 - $60.27 $70,985 - $94,443	1,567 Added 172.2%	2,477 $140,000
Q3 2020 Oct 27, 2020	SELL	$47.45 - $62.95 $105,006 - $139,308	-2,213 Reduced 70.86%	910 $43,000
Q2 2020 Jul 16, 2020	BUY	$46.85 - $61.05 $104,756 - $136,507	2,236 Added 252.09%	3,123 $184,000
Q1 2020 Apr 27, 2020	SELL	$41.6 - $63.4 $80,412 - $122,552	-1,933 Reduced 68.55%	887 $41,000
Q4 2019 Jan 30, 2020	BUY	$53.85 - $65.27 $107,700 - $130,539	2,000 Added 243.9%	2,820 $170,000
Q2 2019 Aug 05, 2019	SELL	$62.09 - $86.14 $43,463 - $60,298	-700 Reduced 46.05%	820 $53,000
Q1 2019 May 01, 2019	SELL	$52.92 - $81.17 $29,106 - $44,643	-550 Reduced 26.57%	1,520 $123,000
Q4 2018 Feb 05, 2019	SELL	$43.37 - $59.54 $41,331 - $56,741	-953 Reduced 31.52%	2,070 $111,000
Q3 2018 Nov 01, 2018	BUY	$42.88 - $53.7 $85,760 - $107,400	2,000 Added 195.5%	3,023 $156,000
Q2 2018 Jul 30, 2018	SELL	$40.53 - $50.7 $36,477 - $45,630	-900 Reduced 46.8%	1,023 $42,000
Q1 2018 May 08, 2018	SELL	$44.08 - $55.05 $101,384 - $126,615	-2,300 Reduced 54.46%	1,923 $85,000
Q4 2017 Feb 13, 2018	BUY	$50.3 - $64.39 $45,270 - $57,951	900 Added 27.08%	4,223 $212,000
Q3 2017 Nov 15, 2017	BUY	$45.56 - $59.57 $151,395 - $197,951	3,323 New	3,323 $182,000
Q3 2017 Nov 14, 2017	SELL	$45.56 - $59.57 $94,445 - $123,488	-2,073 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	2,073	2,073 $109,000

Others Institutions Holding IONS

# of Institutions

401

Shares Held

146M

Call Options Held

916K

Put Options Held

552K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC Ionis Pharmaceuticals Inc Transaction History